Page 2 - Treatment Acceleration Program News Today

Supply chain capacity and projection of shortages . Thank you for that question and statements, senator murray. Yes, as i stated, we continue to have a work in progress as we build the testing capacity. We have established the targets with the states of over 12 million tests over the next four weeks. We think those targets are going to be good in may and june, but as dr. Fauci said, we really have to be evidence based. We expect those targets to go up as we progressively open, as communities go ...

There are granting now that they reopened too quickly. Reporter yeah. Thats one of the questions there. We do know they had a stayathome order that did expire in the middle of may, and then they are saying there was a twoweek lag after that and thats when we started to see the cases really rise back up here in arizona and thats the reason for this concern. Theres also been a nonlinear plan on how to deal with masks. It is not mandated across the state of arizona to wear a mask and one of the que...

As federal COVID-19 public health emergency support and waivers expire, healthcare providers, payers, and other private stakeholders can strategically respond.

/PRNewswire/ -- Major players in the coronavirus (COVID-19) current therapy market are Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune,...

/PRNewswire/ -- As per Facts and Factors study, The global Peptide Synthesis market size was estimated to be worth roughly USD 509.74 million in 2021 and is...

/PRNewswire/ -- The "2021 Medical Devices Research Review" report has been added to ResearchAndMarkets.coms offering. The global contract manufacturing of...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Press release content from Business Wire. The AP news staff was not involved in its creation. Worldwide COVID-19 Diagnostics and Kits Industry to 2025 - by Product Type, Testing Type, End-user and Region - ResearchAndMarkets.com April 29, 2021 GMT DUBLIN--(BUSINESS WIRE)--Apr 29, 2021-- This report examines the current and future market potential of COVID-19 diagnostics. It offers an analysis of the competitive environment, regulatory scenario, technologies, and the drivers and restraints in th...

The US Food and Drug Administration (FDA) has approved Investigational New Drug (IND) application submitted by Airway Therapeutics to develop AT-100 (rhSP-D) for treating patients with Covid-19.

To embed, copy and paste the code into your website or blog: Under President Joe Biden, pharmaceutical regulation may see increased FDA guidance, new strategies to speed up innovation and regulatory review, and a renewed focus on diseases with unmet needs, among other expectations. With President Joe Biden sworn in as the 46th US president, attention has turned to what actions he will take in his first 100 days in office, and beyond. While much of the president’s focus will initially be on th...